

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

Claims 1-4 (Cancelled).

5(Previously presented). The method according to claim 11, wherein the vascular endothelial growth factor (VEGF) inhibitor is selected from the group consisting of 3,7-dimethyl-1-propargylxanthine (DMPX), an A2-antagonist 7-(betahydroxyethyl) theophylline, 8-phenyltheophylline, the adenosine A2 receptor antagonist 8-(3-chlorostyryl) caffeine (CSC), theobromine, an antagonistic VEGF variant, soluble VEGF receptor sFLT-1, Tranilast, 8-(3-oxo-4,5,6-trihydroxy-3h-xanthen-9-yl)-1-naphthoic acid, suramin and platelet factor-4.

Claims 6-8 (Cancelled).

9(Currently amended). A method for inhibiting angiogenesis in adipose tissue in mammals, comprising administering to a subject a pharmaceutical composition, which comprises leptin, or a fragment, homologue or chemical derivative thereof which has the activity of leptin, and optionally, an inhibitor of angiogenesis, in a suitable dosage form and by a suitable route of administration to inhibit angiogenesis in

adipose tissue by inducing angiopoietin-2 (Ang-2), wherein the leptin homologue has at least 90% sequence identity with the sequence of leptin and the chemical derivative of leptin has one or more chemical moieties attached to leptin.

Claim 10 (Cancelled).

11(Previously presented). The method of claim 12, wherein the inhibitor of angiogenesis is a VEGF inhibitor.

12(Previously presented). The method of claim 9, wherein said pharmaceutical composition comprises an inhibitor of angiogenesis.

Claims 13 and 14 (Cancelled).

15(Previously presented). The method of claim 9, wherein said derivative has one or more chemical moieties attached to leptin.

16(Previously presented). The method of claim 9, wherein said one or more chemical moieties attached to leptin are water soluble polymers.

17(Previously presented). The method of claim 16, wherein said water soluble polymers are polyethylene glycol that form pegylated derivatives of leptin.

Appln. No. 10/070,295  
Amd. dated August 1, 2008  
Reply to Office Action of November 2, 2007

Claim 18 (Cancelled).

19(New). The method of claim 9, wherein, in the adipose tissue in which angiogenesis is inhibited, VEGF is absent.